787 related articles for article (PubMed ID: 26166767)
21. Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.
Morrey JD; Motter NE; Chang S; Fairman J
Antiviral Res; 2011 Jun; 90(3):227-30. PubMed ID: 21545812
[TBL] [Abstract][Full Text] [Related]
22. Single dose HBsAg CS-γ-PGA nanogels induce potent protective immune responses against HBV infection.
Wang H; Han Q; Zhao H; Xu D; Zhang J
Eur J Pharm Biopharm; 2018 Mar; 124():82-88. PubMed ID: 29247691
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
[TBL] [Abstract][Full Text] [Related]
24. Effect of the hepatitis B virus S‑ecdCD40L vaccine therapy in HBV transgenic mice: A vaccine‑induced activation of antigen presenting dendritic cells.
Guan H; Lan S; Wu J; Tang B; Xu Y
Mol Med Rep; 2017 Nov; 16(5):6102-6108. PubMed ID: 28849136
[TBL] [Abstract][Full Text] [Related]
25. [Antivirus effect of plasmid co expressing hepatitis B surface antigen and granulocyte macrophage-colony stimulating factor].
Qing YL; Zhao JJ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2004 Apr; 12(4):201-4. PubMed ID: 15099465
[TBL] [Abstract][Full Text] [Related]
26. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.
Backes S; Jäger C; Dembek CJ; Kosinska AD; Bauer T; Stephan AS; Dišlers A; Mutwiri G; Busch DH; Babiuk LA; Gasteiger G; Protzer U
Vaccine; 2016 Feb; 34(7):923-32. PubMed ID: 26776470
[TBL] [Abstract][Full Text] [Related]
27. A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine.
Choi YM; Kim DH; Jang J; Kim BJ
Front Immunol; 2023; 14():1155637. PubMed ID: 37334373
[TBL] [Abstract][Full Text] [Related]
28. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients.
Verkade MA; van de Wetering J; Klepper M; Vaessen LM; Weimar W; Betjes MG
Kidney Int; 2004 Aug; 66(2):614-21. PubMed ID: 15253714
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
[TBL] [Abstract][Full Text] [Related]
32. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
[TBL] [Abstract][Full Text] [Related]
34. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
Li X; Yang X; Li L; Liu H; Liu J
Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
[TBL] [Abstract][Full Text] [Related]
35. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
[TBL] [Abstract][Full Text] [Related]
36. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis.
Cruciani M; Mengoli C; Serpelloni G; Mazzi R; Bosco O; Malena M
Vaccine; 2007 Jan; 25(4):709-18. PubMed ID: 16963165
[TBL] [Abstract][Full Text] [Related]
37. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.
Malanchère-Brès E; Payette PJ; Mancini M; Tiollais P; Davis HL; Michel ML
J Virol; 2001 Jul; 75(14):6482-91. PubMed ID: 11413315
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.
Akbar SM; Abe M; Masumoto T; Horiike N; Onji M
J Hepatol; 1999 May; 30(5):755-64. PubMed ID: 10365798
[TBL] [Abstract][Full Text] [Related]
39. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
Oka Y; Akbar SM; Horiike N; Joko K; Onji M
Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
[TBL] [Abstract][Full Text] [Related]
40. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220.
Overton ET; Kang M; Peters MG; Umbleja T; Alston-Smith BL; Bastow B; Demarco-Shaw D; Koziel MJ; Mong-Kryspin L; Sprenger HL; Yu JY; Aberg JA
Vaccine; 2010 Aug; 28(34):5597-604. PubMed ID: 20600512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
